IND-Enabling Nonclinical Studies: How can the Industry Prepare? Upcoming Webinar Hosted by Xtalks

Share Article

In this webinar, learn how to best prepare for conducting and managing IND-enabling nonclinical studies and meeting FDA guidelines. Attendees will gain insights into critical aspects of nonclinical laboratory qualification and obtaining comparable laboratory quotes. Attendees will learn the logistics of study startup through reporting. The featured speakers will discuss monitoring best practices and ensuring GLP compliance and regulatory acceptance by the FDA.

It’s important for sponsors to provide appropriate oversight of their studies to verify that they are receiving adequate attention.

Completing nonclinical studies to support FDA investigational new drug applications is an essential milestone for progressing a new drug into the clinic. Conducting studies according to relevant regulatory requirements, such as good laboratory practices, and guidelines from the FDA and the International Council for Harmonisation is essential for ensuring acceptance by the FDA and that IND-opening clinical trials can proceed without a clinical hold.

For outsourced animal studies, it is tempting to rely solely upon the nonclinical laboratory for study design, conduct, and reporting. However, these laboratories and their study directors have many competing pressures, and it’s important for sponsors to provide appropriate oversight of their studies to verify that they are receiving adequate attention.

Also, IND-enabling studies require significant input on design, conduct, and reporting from the sponsor. It is important to confirm that a lab has appropriate processes and controls in place to conduct studies that meet the applicable regulatory requirements or, if not, to provide even greater input and oversight than might otherwise be required. Although the scientific results are dependent upon the drug, this webinar will provide practical guidance for designing, contracting, monitoring, and reporting nonclinical/toxicology studies to ensure regulatory acceptance by the FDA.

Register for this webinar to find out how to best prepare for conducting and managing IND-enabling nonclinical studies and meeting FDA guidelines.

Join William Salminen, PhD, DABT, PMP, Vice President, Nonclinical Safety and Toxicology, Premier Consulting; and Andrew Emanuel, Senior Director, Nonclinical Development, Premier Partners, for the live webinar on Friday, March 17, 2023, at 11am EDT (4pm CET/EU-Central).

For more information, or to register for this event, visit IND-Enabling Nonclinical Studies: How can the Industry Prepare?

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Vera Kovacevic
Xtalks
+1 (416) 977-6555 x371
Email >
Visit website